NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary Chapter: 6 - Endocrine system 
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing

06.04.01.01 Oestrogens and HRT

Bijuve capsules® (Contains estradiol 1mg & progesterone 100mg)

Formulary

Restricted ItemFor use where compliance is an issue with the separate products only.

Continuous combined hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses.

 

Entry reviewed: September 2022

Elleste Duet Conti tablet® (Contains estradiol 2mg & norethisterone 1mg)

Formulary

Entry reviewed: September 2022

Elleste Duet tablets® (Contains Estradiol 1mg/2mg & norethisterone 1mg)

Formulary

 

Entry reviewed: September 2022

Estradiol 1mg / 2mg tablets (Progynova® Elleste Solo®)

 
Formulary

Green For HRT

Amber SCG Prescribing in Gender Dysphoria only on the advice of a specialist centre under shared care arrangements

 

Most cost effective brand to be advised by OptimiseRx in Primary care

 

Entry reviewed: September 2022

Evorel Conti patch® (Contains estradiol 50mcg & norethisterone 170mcg)
(Estradiol with norethisterone)

Formulary

Lowest cost continuous combined patch

 

Entry reviewed: September 2022

Evorel patches® (Contains estradiol 25/50/75/100mcg)

Formulary

Entry reviewed: September 2022

Evorel Sequi patches® (Contains estradiol 50mcg & norethisterone 170mcg)

Formulary

Entry reviewed: September 2022

Femoston Conti tablets®

Formulary

Entry reviewed: September 2022

Femoston tablets® (Contains estradiol 1mg/2mg & dydrogesterone 10mg)

Formulary

Entry reviewed: september 2022

FemSeven patch® (Contains estradiol 50/75/100mcg)

 
Formulary

GreenFor HRT

Restricted Item Reserved for patients with compliance issues with twice weekly dosing or those with skin reactions to other patches

Amber SCG When being used for Gender Dysphoria, must only be prescribed on the advice of a specialist centre under shared care arrangements

 

Entry reviewed: September 2022

Kliofem tablets® (Contains estradiol 2mg & norethisterone 1mg)

Formulary

Entry reviewed: September 2022

Kliovance tablets® (Contains estradiol 1mg & norethisterone 500mcg)

Formulary

Entry reviewed: September 2022

Lenzetto spray® (Contains estradiol 1.53mg per actuation)

Formulary

Restricted Item  RESTRICTED USE as a transdermal HRT option for the treatment of oestrogen deficiency symptoms in postmenopausal women (in women at least 6 months since last menses or surgical menopause, with or without a uterus) only when alternative transdermal products are not tolerated/contraindicated.

 

Entry reviewed: June 2023

Sandrena gel (for transdermal use)® (Contains estradiol 500mcg/1mg)

 
Formulary

Green For HRT

Amber SCG When being used for Gender Dysphoria, must only be prescribed on the advice of a specialist centre under shared care arrangements

 

Entry reviewed: September 2022

 

Oestrogel pump pack (for transdermal use) ® (Contains estradiol 0.06% as gel / 750mcg per actuation)

 
Formulary

Green For HRT

Amber SCG When being used for Gender Dysphoria, must only be prescribed on the advice of a specialist centre under shared care arrangements

 

Entry reviewed: September 2022

Non formulary items

Clinorette tablets® (Contains estradiol 2mg & norethisterone 1mg)

 
Non Formulary

Entry reviewed: September 2022

Conjugated oestrogen tablets

 
Non Formulary

Assessed September 2022: No longer recommended for prescribing (equine oestrogen less suitable)

Elinzanetant (Lynkuet®)

 
Non Formulary

Non-hormonal treatment for moderate to severe vasomotor symptoms associated with menopause - Not to be prescribed pending outcome of NICE appraisal.

 Project information | Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544] | Guidance | NICE

Entry reviewed: August 2025

Fezolinetant (Veoza®)

 
Non Formulary

Non-hormonal treatment for moderate to severe vasomotor symptoms associated with menopause - Not to be prescribed pending outcome of NICE appraisal expected in May 2025.

https://www.nice.org.uk/guidance/indevelopment/gid-ta11058 

 

Entry reviewed: August 2024

Tibolone tablets (Livial®)

 
Non Formulary

Entry reviewed: September 2022

Tridestra tablets®

 
Non Formulary

Assessed September 2022: No longer recommended as an option for HRT in BLMK

The brand Tridestra (estradiol with medroxyprogesterone) has been discontinued 31/12/2024.

https://www.sps.nhs.uk/shortages/discontinuation-of-tridestra-tablets/

06.04.01.01 Hormone replacement therapy
06.04.01.01 Ethinylestradiol
06.04.01.01 Raloxifene
Classifications
May be initiated in any care setting
Specialist to advise therapy and provide first 28 days supply, continuation in Primary Care
Specialist to initiate and stabilise medicine prior to continuation in Primary Care
To be prescribed as per Shared Care Guidance. If no SCG in place status reverts to red.
Red medicines are designated as specialist only medicines which should only be prescribed by a specialist, usually within secondary care (either due to the requirement for specialist knowledge, long-term monitoring requirements, or restrictions that mean medicine supplies are only available to hospitals).
A decision has been made either locally and/or nationally not to routinely commission this preparation. Do not prescribe.
To be purchased over the counter. May be prescribed for chronic, long term conditions or on admission to hospital if essential.